About TALZENNA® (talazoparib) TALZENNA is an oral inhibitor of poly ADP-ribose polymerase (PARP), which plays a role in DNA damage repair. Preclinical studies have demonstrated that TALZENNA blocks ...

MagnetisMM-32 is an open-label, multicenter, randomized Phase 3 study to evaluate the efficacy and safety of ELREXFIO monotherapy versus investigator’s choice among three standard-of-care regimens ...

Pfizer supports the global healthcare community’s independent initiatives (e.g., research, quality improvement or education) to improve patient outcomes in areas of unmet medical need that are aligned ...

It started with a breakthrough. The year was 1849, and people everywhere were getting sick to their stomachs. In the days before widespread refrigeration, a simple meal of meat and potatoes could ...

This information is intended for media professionals only. To ensure that customers, investors, and others receive the appropriate attention, Pfizer media contacts may ONLY respond to calls and emails ...

Eight years ago, few people had heard of transthyretin amyloid cardiomyopathy (ATTR-CM), and it was rarely diagnosed in cardiology practice. 1,2 Today, it is a treatable condition that cardiologists ...

Third mRNA vaccine collaboration between the companies aims to accelerate development of an improved vaccine for shingles, a debilitating, disfiguring and painful disease that affects people all over ...

In a Phase 3 trial, Pfizer and BioNTech’s combination vaccine candidate against influenza and COVID-19 met one of its two primary immunogenicity objectives The trial did not meet one of its primary ...

ABRYSVO, a bivalent vaccine, maintained consistently high protective efficacy for both RSV A and RSV B disease through two seasons after a single dose. ABRYSVO efficacy was 77.8% against RSV lower ...

Approval expands HYMPAVZI use to now include people with hemophilia A or B ages 12 years and older with inhibitors and pediatric patients (ages 6 to 11 years) with or without inhibitors HYMPAVZI is ...

Approval is based on positive data from the Phase 3 ECHELON-3 trial, which demonstrated ADCETRIS regimen reduced the risk of death by 37%, a statistically significant, clinically meaningful ...